Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHaiwen Huang

Discussion

Loading...

Member takes

Overview

Efficacy and safety findings from the Pola-AR2 regimen in frail patients with DLBCL suggest promising outcomes.

Key Points

  • This study aims to evaluate the efficacy and safety of the Pola-AR2 regimen in frail patients with diffuse large B-cell lymphoma (DLBCL).
  • Assessing 13 frail patients with newly diagnosed DLBCL
  • Administering the Pola-AR2 regimen every 21 days for up to 6 cycles
  • Assessing treatment response via positron emission tomography/computed tomography after four cycles
  • 69.2% of patients achieved complete response after treatment
  • Overall response rate was 92.3% among evaluable patients
  • No significant adverse events were observed during treatment

Cite This Study

Haiwen Huang (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236def5https://doi.org/10.1182/blood-2025-3742
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026
  2. 2Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study2025
  3. 3Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates2025
  4. 4Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study2025
  5. 5Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study2025